Nanomedicine to aid immunogenic cell death (ICD)-based anticancer therapy

被引：3

作者：

Demuynck, Robin ^{[1
,2
]}

Engelen, Yanou ^{[3
]}

Skirtach, Andre G. ^{[2
,4
]}

De Smedt, Stefaan C. ^{[3
]}

Lentacker, Ine ^{[3
]}

Krysko, Dmitri, V ^{[1
,2
]}

机构：

[1] Univ Ghent, Fac Med & Hlth Sci, Dept Human Struct & Repair, Anat & Embryol Unit,Cell Death Invest & Therapy L, B-9000 Ghent, Belgium

[2] Canc Res Inst Ghent, B-9000 Ghent, Belgium

[3] Univ Ghent, Fac Pharmaceut Sci, Ghent Res Grp Nanomed, Lab Gen Biochem & Phys Pharm, B-9000 Ghent, Belgium

[4] Univ Ghent, Fac Biosci Engn, Dept Biotechnol, NanoBioTechnol Lab, B-9000 Ghent, Belgium

来源：

TRENDS IN CANCER | 2024年 / 10卷 / 06期

关键词：

CANCER;

D O I：

10.1016/j.trecan.2024.03.003

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immunogenic cell death (ICD) is emerging as a key component of antitumor therapy that harnesses the immune system of the patient to combat cancer. In recent years, several efforts were made to improve the ICD-based therapies. Here, we discuss how nanomaterial-based strategies increase the efficacy of ICD and highlight their benefits and challenges.

引用

页码：486 / 489

页数：4

共 50 条

[1] Anticancer metal drugs and immunogenic cell death
Terenzi, Alessio
Pirker, Christine
Keppler, Bernhard K.
Berger, Walter
JOURNAL OF INORGANIC BIOCHEMISTRY, 2016, 165 : 71 - 79
[2] Immunogenic Apoptotic Cell Death and Anticancer Immunity
Vandenabeele, Peter
Vandecasteele, Katrien
Bachert, Claus
Krysko, Olga
Krysko, Dmitri V.
APOPTOSIS IN CANCER PATHOGENESIS AND ANTI-CANCER THERAPY: NEW PERSPECTIVES AND OPPORTUNITIES, 2016, 930 : 133 - 149
[3] Immunogenic cell death inducers as anticancer agents
Kepp, Oliver
Senovilla, Laura
Kroemer, Guido
ONCOTARGET, 2014, 5 (14) : 5190 - 5191
[4] Polysulfonium: Unveiling a Bioactive Polymer to Induce Immunogenic Cell Death for Anticancer Therapy
Lv, Xueli
Yin, Renyong
Lin, Min
Guo, Zhihui
Tian, Yongchang
Zhang, Peng
Xiao, Chunsheng
Sun, Jing
Chen, Xuesi
NANO LETTERS, 2024, 24 (34) : 10664 - 10673
[5] Immunogenic Tumor Cell Death for Optimal Anticancer Therapy: The Calreticulin Exposure Pathway
Zitvogel, Laurence
Kepp, Oliver
Senovilla, Laura
Menger, Laurie
Chaput, Nathalie
Kroemer, Guido
CLINICAL CANCER RESEARCH, 2010, 16 (12) : 3100 - 3104
[6] Discovery of immunogenic cell death-inducing ruthenium-based photosensitizers for anticancer photodynamic therapy
Konda, Prathyusha
Lifshits, Liubov M.
Roque, John A., III
Cole, Houston D.
Cameron, Colin G.
McFarland, Sherri A.
Gujar, Shashi
ONCOIMMUNOLOGY, 2021, 10 (01):
[7] Nanomedicine-mediated immunogenic cell death and its combination with immune checkpoint blockade therapy
CHEN JunBin
ZHANG YuXi
SU Miao
ZHU YueQiang
YANG XianZhu
ScienceChina(TechnologicalSciences), 2024, 67 (08) : 2350 - 2362
[8] Nanomedicine-mediated immunogenic cell death and its combination with immune checkpoint blockade therapy
Chen, JunBin
Zhang, YuXi
Su, Miao
Zhu, YueQiang
Yang, XianZhu
SCIENCE CHINA-TECHNOLOGICAL SCIENCES, 2024, 67 (08) : 2350 - 2362
[9] Induction of immunogenic cell death by novel platinum-based anticancer agents
Chang, Xingyu
Bian, Mianli
Liu, Lijuan
Yang, Jiaqi
Yang, Zhibin
Wang, Zhaoran
Lu, Yunlong
Liu, Wukun
PHARMACOLOGICAL RESEARCH, 2023, 187
[10] Immunogenic Cell Death in Cancer Therapy
Troitskaya, Olga S.
Novak, Diana D.
Richter, Vladimir A.
Koval, Olga A.
ACTA NATURAE, 2022, 14 (01): : 40 - 53

← 1 2 3 4 5 →